# Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study

> **NCT00076440** · PHASE2 · COMPLETED · sponsor: **Voyager Pharmaceutical Corporation** · enrollment: 90 (—)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Leuprolide acetate

## Key facts

- **NCT ID:** NCT00076440
- **Lead sponsor:** Voyager Pharmaceutical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12
- **Primary completion:** 2007-03
- **Final completion:** 2007-03
- **Target enrollment:** 90 (—)
- **Last updated:** 2009-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00076440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00076440, "Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (ALADDIN) VP 104 Study". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00076440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*